drugset / Trial / NCT00349089

Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy

NCT00349089

Phase 2 Completed 132 enrolled Thoraxklinik-Heidelberg gGmbH
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this randomized phase II trial is to determine the clinical feasibility - in terms of patients without dose limiting toxicities or premature treatment withdrawal or death - of the combination of Cisplatin and Pemetrexed and of the combination of Cisplatin and Vinorelbine. The combination of Cisplatin / Pemetrexed is assumed to be distinctly less toxic than Vinorelbine / Cisplatin.

Timeline

Start
2006-09-26
Primary completion
2014-04-14
Completion
2014-04-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 50 mg/m2
Subject Cisplatin Other / unclassified 75 mg/m2
Subject Pemetrexed Small molecule 500 mg/m2
Comparator Vinorelbine Small molecule 25 mg/m2